~~<i id='1ACA0CEFCC'><strike id='1ACA0CEFCC'><tt id='1ACA0CEFCC'><pre id='1ACA0CEFCC'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

Wikipedia

fashion

author：explore 2025-10-02 22:39:44 - browse：1

Acadia Pharmaceuticals said Monday that its approved medicine called Nuplazid failed to improve the social and emotional symptoms of schizophrenia in a late-stage clinical trial.

The negative outcome of the Phase 3 study represents a setback in the company’s efforts to expand the use of Nuplazid into the treatment of schizophrenia. The medicine is currently approved to treat hallucinations and delusions associated with Parkinson’s disease psychosis.

“We are disappointed the trial did not meet its primary endpoint given the significant unmet need in patients with negative symptoms of schizophrenia,” said Acadia CEO Steve Davis, in a statement.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： STAT Summit: Ending the crisis of Black deaths in the U.S.

Wikipedia

focus

leisure time

hotspot

explore

hotspot

ChristineKao/STATThere’saspecterhauntingWallStreet.Itstartedinbiotech,wherecompaniesmakingdrugsforth

WSS

Ancient Greek ideas underpin modern concepts of pregnancy

Readout LOUD podcast: Live from the 2023 STAT Summit

The untold story of TV’s first prescription drug ad

Cassava Sciences’ Alzheimer’s clinical trials should be halted

Questions loom on AstraZeneca cancer drug as safety concerns ebb

First over

Wikipedia

fashion

Wikipedia

Malaria cases in Florida and Texas: Here’s what you need to know

He's 19 months old and has one of the world’s rarest diseases

Sports medicine is finally prioritizing gender equality

STAT Readout Newsletter: Biotech news today

Heart attack and stroke risk calculators need revising

Immune cells and nerve overgrowth may explain recurring UTI pain

New air purifier tech could be key to improving indoor air quality

IVF doctors demand details after CooperSurgical lawsuit

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Smaller biotechs seek to piggyback on weight loss drug boom

focus

Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

Why Talkspace is targeting Medicare, a tricky market

Why a market frenzy over new weight loss drugs defies logic

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

Stem cell biologist probes earliest stages of human development

STAT Summit: The economic case for universal basic health care

leisure time

hotspot

explore

hotspot